Calidi Biotherapeutics (CLDI) Interest Coverage Ratio (2022 - 2025)
Calidi Biotherapeutics' quarterly Interest Coverage Ratio came in at 893.2 in Q4 2025, down 2273.88% year-on-year from 41.09 in Q4 2024, and down 448.52% quarter-over-quarter from 162.84 in Q3 2025.
Calidi Biotherapeutics has reported Interest Coverage Ratio for 4 years, with the latest figure at 893.2 in Q4 2025.
- For the quarter ending Q4 2025, Interest Coverage Ratio fell 2273.88% year-over-year to 893.2; the trailing twelve-month figure through Dec 2025 stood at 204.44 (down 392.9% YoY), and the FY2025 full-year result was 266.32, down 586.09% from the prior year.
- Interest Coverage Ratio for Q4 2025 stood at 893.2, down from 162.84 in the prior quarter.
- The five-year high for Interest Coverage Ratio was 38.97 in Q4 2023, with the low at 893.2 in Q4 2025.
- Average Interest Coverage Ratio over 4 years is 136.39, with a median of 45.22 recorded in 2024.
- Year-over-year, Interest Coverage Ratio jumped 183.12% in 2023 and plunged 2273.88% in 2025.
- Tracing CLDI's Interest Coverage Ratio over 4 years: stood at 46.88 in 2022, then jumped by 183.12% to 38.97 in 2023, then sank by 196.56% to 37.63 in 2024, then tumbled by 2273.88% to 893.2 in 2025.
- The last three Interest Coverage Ratio figures came in at 893.2 (Q4 2025), 162.84 (Q3 2025), and 195.31 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - | -129.79 |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - | - |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn | 3.58 |
| 4 | Nanobiotix | 2,282.79 Bn | 2,282.72 Bn | - | - |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - | -258.33 |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn | - |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn | 49.84 |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - | 11.50 |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn | 3.88 |
| 10 | Calidi Biotherapeutics | - | - | - | -893.20 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -893.20 |
| Sep 30, 2025 | -162.84 |
| Jun 30, 2025 | -195.31 |
| Mar 31, 2025 | -148.88 |
| Dec 31, 2024 | -37.63 |
| Sep 30, 2024 | -53.33 |
| Jun 30, 2024 | -34.98 |
| Mar 31, 2024 | -43.56 |
| Dec 31, 2023 | 38.97 |
| Sep 30, 2023 | -32.38 |
| Jun 30, 2023 | -31.43 |
| Mar 31, 2023 | -27.07 |
| Dec 31, 2022 | -46.88 |
| Sep 30, 2022 | -240.90 |